Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice

Experimental Neurology

Volumn 203, Issue 1, 2007, Pages 241-245

  Dall'Igna, Oscar P ^a   Fett, Paulo ^a   Gomes, Marcio W ^a   Souza, Diogo O ^a   Cunha, Rodrigo A ^b   Lara, Diogo R ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

amyloid; A2A receptor; Adenosine; Alzheimer's disease; Caffeine; Memory; Neuroprotection

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN[25-35]; CAFFEINE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; IN VIVO STUDY; MALE; MENTAL PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TASK PERFORMANCE;

ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PROTEIN; ANIMALS; AVOIDANCE LEARNING; BRAIN; CAFFEINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; MALE; MAZE LEARNING; MICE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TREATMENT OUTCOME; TRIAZOLES;

EID: 33751427701     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.08.008     Document Type: Article

References (28)

1. Angelucci M.E., Vital M.A., Cesario C., Zadusky C.R., Rosalen P.L., and Da Cunha C. The effect of caffeine in animal models of learning and memory. Eur. J. Pharmacol. 373 (1999) 135-140
2. Angulo E., Casadó V., Mallol J., Canela E.I., Vinals F., Ferrer I., Lluis C., and Franco R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 13 (2003) 440-451
3. 2A receptor heteromers. J. Neurosci. 26 (2006) 2080-2087
4. Coleman P., Federoff H., and Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63 (2004) 1155-1162
5. Cunha R.A. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal. 1 (2005) 111-134
6. 2A receptor blockade of β-amyloid neurotoxicity. Br. J. Pharmacol. 138 (2003) 1207-1209
7. Dall'Igna O.P., Hoffmann A., da Silva A.L., Souza D.O., and Lara D.R. β-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. Neurodegener. Dis. 1 (2004) 38-43
8. de Oliveira R.V., Dall'Igna O.P., Tort A.B., Schuh J.F., Neto P.F., Santos Gomes M.W., Souza D.O., and Lara D.R. Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. Behav. Pharmacol. 16 (2005) 79-84
9. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
10. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
11. Harkany T., Hortobagyi T., Sasvari M., Konya C., Penke B., Luiten P.G., and Nyakas C. Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 23 (1999) 963-1008
12. Hughes R.N. The value of spontaneous alteration behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Behav. Rev. 28 (2004) 497-505
13. Johnson-Kozlow M., Kritz-Silverstein D., Barrett-Connor E., and Morton D. Coffee consumption and cognitive function among older adults. Am. J. Epidemiol. 156 (2002) 842-850
14. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 (2003) 1281-1291
15. Kazlauckas V., Schuh J., Dall'Igna O.P., Pereira G.S., Bonan C.D., and Lara D.R. Behavioral and cognitive profile of mice with high and low exploratory phenotypes. Behav. Brain Res. 162 (2005) 272-278
16. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004) 569-580
17. Kopf S.R., Melani A., Pedata F., and Pepeu G. Adenosine and memory storage: effects of A1 and A2 receptor antagonists. Psychopharmacology 146 (1999) 214-219
18. Maia L., and de Mendonça A. Does caffeine intake protect from Alzheimer's disease?. Eur J. Neurol. 9 (2002) 377-382
19. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706 (1996) 181-193
20. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. 2nd edn. (2001), Academic Press, San Diego
21. 2A receptors. Neurobiol. Aging 26 (2005) 957-964
22. 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J. Neurochem. 88 (2004) 1151-1158
23. 2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J. Neurophysiol. 90 (2003) 1295-1303
24. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 132 (2005) 893-903
25. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 95 (2005) 919-929
26. Solinas M., Ferré S., You Z.B., Karcz-Kubicha M., Popoli P., and Goldberg S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neurosci. 22 (2002) 6321-6324
27. Svenningsson P., Nomikos G.G., and Fredholm B.B. Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79 (1997) 753-764
28. Xu K., Xu Y.H., Chen J.F., and Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16